Candida albicans phosphomannan complex as a vaccine
AssigneeThe Research and Development Institute, Inc.
InventorsJim E. Cutler, Yongmoon Han
Life of this patent
Estimating the term…
Abstract
A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.
Claims21
A vaccine for treatment of candidiasis comprising a pharmaceutically effective amount of the mannan portion of the phosphomannan complex of Candida which elicits an immune response.
A vaccine for treatment of disseminated Candidiasis comprising a pharmaceutical effective amount of an epitope of Candida albicans comprising a beta 1,2-trimannose or acid stable epitopes thereof that elicit an immune response.
A therapeutic composition for treatment of disseminated Candidiasis comprising a pharmaceutical effective amount of passive humoral antibodies to Candida albicans directed against a beta 1,2-trimannose or an epitope in the acid stable region of the mannan portion of the phosphomannan complex of Candida albicans that elicits an immune response.
Isolated protective antibodies for passive protection against hematogenous disseminated candidiasis and mucocutaneous candidiasis.
Monoclonal antibodies specific for mannan epitopes in the acid stable portion of the mannan epitope and β-1,2-linked tri, tetra- and penta-mannosyl residues in the acid labile part of the mannan portion of the phosphomannoprotein complex.
A monoclonal antibody specific for C. albicans phosphomannoprotein.
A method for immunization against candidiasis comprising generating Candida albicans phosphomannan complex neutralizing antibodies.
Dependencies are inferred from the claim text.